{"id":"iron-isomaltoside-monofer","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hypophosphatemia"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL4298046","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Iron isomaltoside consists of iron(III) oxyhydroxide stabilized by isomaltoside, a carbohydrate ligand. The complex protects iron from premature release in the bloodstream while allowing controlled iron delivery to erythroid precursor cells and iron storage sites. This mechanism enables rapid iron repletion with a favorable safety profile compared to older iron dextran formulations.","oneSentence":"Iron isomaltoside is an iron carbohydrate complex that delivers iron to iron-deficient patients by binding iron in a stable complex that is taken up by iron-transporting cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:11.202Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Iron deficiency anemia in patients with chronic kidney disease"},{"name":"Iron deficiency anemia in patients intolerant to or unresponsive to oral iron"}]},"trialDetails":[{"nctId":"NCT06350955","phase":"PHASE4","title":"IV Iron-induced Hypophosphatemia After RYGB","status":"RECRUITING","sponsor":"Lucie Favre","startDate":"2024-05-02","conditions":"Hypophosphatemia, Roux-en-Y Gastric Bypass","enrollment":94},{"nctId":"NCT04608539","phase":"PHASE4","title":"A Clinical Trial Assessing the Efficacy of Intravenous Iron for the Treatment of Anemia Following Cardiac Surgery","status":"COMPLETED","sponsor":"Michael Kremke","startDate":"2021-05-21","conditions":"Anemia Postoperative","enrollment":110},{"nctId":"NCT03957057","phase":"PHASE3","title":"Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2020-09-10","conditions":"Postpartum Anemia Nos, Iron-deficiency","enrollment":300},{"nctId":"NCT04206228","phase":"PHASE2","title":"Intravenous Iron Supplement for Iron Deficiency in Patients With Severe Aortic Stenosis","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2020-01-02","conditions":"Severe Aortic Stenosis, Iron-deficiency","enrollment":149},{"nctId":"NCT03610230","phase":"NA","title":"Iron Isomaltoside Compared With Iron Sucrosein Peritoneal Dialysis Patients","status":"TERMINATED","sponsor":"The University of Hong Kong","startDate":"2019-02-01","conditions":"Iron Deficiency Anemia Treatment","enrollment":16},{"nctId":"NCT02940886","phase":"PHASE3","title":"Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2016-11-08","conditions":"Iron Deficiency Anaemia, Iron Deficiency Anemia","enrollment":1512},{"nctId":"NCT02940860","phase":"PHASE3","title":"Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2016-11-29","conditions":"Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease","enrollment":1538},{"nctId":"NCT02862665","phase":"NA","title":"Effect of Perioperative Iron Isomaltoside 1000 Administration on Transfusion Requirements in Patients Undergoing Complex Valvular Heart Surgery: a Randomized Clinical Trial","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-08","conditions":"Complex Valvular Heart Surgery","enrollment":214},{"nctId":"NCT03565354","phase":"PHASE3","title":"Efficacy of Preoperative Intravenous Iron in Anaemic Colorectal Cancer Surgical Patients","status":"COMPLETED","sponsor":"Prince of Wales Hospital, Shatin, Hong Kong","startDate":"2018-07-01","conditions":"Anemia, Iron-Deficiency, Colorectal Cancer","enrollment":40},{"nctId":"NCT02962648","phase":"PHASE3","title":"An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2017-01-09","conditions":"Iron Deficiency Anemia, Iron Deficiency Anaemia","enrollment":103},{"nctId":"NCT03237065","phase":"PHASE3","title":"Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2017-10-30","conditions":"Iron Deficiency Anaemia, Iron Deficiency Anemia","enrollment":122},{"nctId":"NCT03238911","phase":"PHASE3","title":"Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2017-10-24","conditions":"Iron Deficiency Anaemia, Iron Deficiency Anemia","enrollment":123},{"nctId":"NCT02546154","phase":"","title":"Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®)","status":"COMPLETED","sponsor":"Pharmacosmos UK Ltd","startDate":"2016-01-22","conditions":"Iron Deficiency Anaemia","enrollment":359},{"nctId":"NCT03470649","phase":"NA","title":"Effect of IV Iron Isomaltoside on Postoperative Anemia in Total Knee Arthroplasty Patients","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2018-03-29","conditions":"Anemia, Knee Arthropathy","enrollment":100},{"nctId":"NCT03094182","phase":"NA","title":"Efficacy of Intravenous Iron Therapy in Maintaining Hemoglobin Concentration on Patients Undergoing Bimaxillary Orthognathic Surgery","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2017-03-02","conditions":"Facial Asymmetry, Retrognathism, Prognathism","enrollment":58},{"nctId":"NCT03229954","phase":"PHASE4","title":"Intravenous Iron Isomaltoside 1000 (Monofer®) Compared With Oral Iron in the Treatment of Postgastrectomy Anemia: An Open-label Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2017-08-28","conditions":"Post Gastrectomy Anemia","enrollment":358},{"nctId":"NCT02130063","phase":"PHASE3","title":"IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2014-05","conditions":"Iron Deficiency Anaemia","enrollment":511},{"nctId":"NCT01895231","phase":"PHASE3","title":"A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-deficient Blood Donors","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2013-06","conditions":"Iron-deficiency","enrollment":107},{"nctId":"NCT03013439","phase":"PHASE1","title":"Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®)","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2017-01-06","conditions":"Anemia, Deficiency Diseases, Anemia, Iron Deficiency","enrollment":24},{"nctId":"NCT01927328","phase":"PHASE4","title":"Iron Replacement in Oesophagogastric Neoplasia","status":"UNKNOWN","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2013-08","conditions":"Anemia, Esophageal Cancer, Gastric Cancer","enrollment":40},{"nctId":"NCT02172001","phase":"PHASE3","title":"A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo","status":"WITHDRAWN","sponsor":"Pharmacosmos A/S","startDate":"","conditions":"Iron Deficiency Anemia","enrollment":""},{"nctId":"NCT01900197","phase":"","title":"Time to Relapse of Iron Deficiency Anemia After Standard Treatment With a New Intravenous Iron (Monofer®)","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2013-08","conditions":"Iron Deficiency Anemia","enrollment":391},{"nctId":"NCT01102413","phase":"PHASE3","title":"Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2010-04","conditions":"Iron Deficiency Anemia, Chronic Kidney Disease","enrollment":351},{"nctId":"NCT01145638","phase":"PHASE3","title":"A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2010-10","conditions":"Non-myeloid Malignancies, Chemotherapy Induced Anaemia","enrollment":350},{"nctId":"NCT01222884","phase":"PHASE3","title":"A Randomized, Comparative, Open-label Study of IV Monofer® Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With IV Iron Sucrose in Subjects With CKD-5D","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2011-06","conditions":"Chronic Kidney Disease Stage 5 (Dialysis Dependent)","enrollment":351},{"nctId":"NCT01895205","phase":"PHASE3","title":"Treatment of Women After Severe Postpartum Haemorrhage","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2013-06","conditions":"Severe Postpartum Haemorrhage","enrollment":13},{"nctId":"NCT01599702","phase":"PHASE3","title":"Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2012-05","conditions":"Inflammatory Bowel Disease","enrollment":21},{"nctId":"NCT01895218","phase":"PHASE3","title":"Treatment of Women After Postpartum Haemorrhage","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2013-06","conditions":"Postpartum Haemorrhage","enrollment":200},{"nctId":"NCT01563367","phase":"PHASE3","title":"A Prospective, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-Anaemic Patients Undergoing Elective or Sub-Acute Coronary Artery Bypass Graft, Valve Replacement or a Combination Thereof","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2012-01","conditions":"Non-anaemic Patients Undergoing Cardiac Surgery","enrollment":74},{"nctId":"NCT01410435","phase":"PHASE3","title":"Safety and Efficacy Extension Study of Iron Isomaltoside 1000 (Monofer®) in Subjects With Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2011-06","conditions":"Inflammatory Bowel Disease, Anaemia","enrollment":39},{"nctId":"NCT01213992","phase":"PHASE1","title":"Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKD","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2012-03","conditions":"Non-dialysis Dependent Chronic Kidney Disease","enrollment":16},{"nctId":"NCT01213979","phase":"PHASE1","title":"Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2012-02","conditions":"Non-hematological Malignancies","enrollment":16},{"nctId":"NCT01280240","phase":"PHASE1","title":"Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2012-03","conditions":"Patients With Chemotherapy Induced Anemia (CIA)","enrollment":11},{"nctId":"NCT01469078","phase":"PHASE1","title":"Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D)","status":"COMPLETED","sponsor":"Pharmacosmos A/S","startDate":"2011-10","conditions":"Chronic Kidney Disease","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"iron isomaltoside(Monofer®)","genericName":"iron isomaltoside(Monofer®)","companyName":"Prince of Wales Hospital, Shatin, Hong Kong","companyId":"prince-of-wales-hospital-shatin-hong-kong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iron isomaltoside is an iron carbohydrate complex that delivers iron to iron-deficient patients by binding iron in a stable complex that is taken up by iron-transporting cells. Used for Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients intolerant to or unresponsive to oral iron.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}